Oruka Therapeutics (NASDAQ:ORKA) Issues Quarterly Earnings Results

Oruka Therapeutics (NASDAQ:ORKA) released its earnings results on Monday. The company reported ($0.63) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.03), FiscalAI reports.

Oruka Therapeutics Trading Up 1.7%

ORKA stock traded up $1.70 on Monday, hitting $104.56. The company’s stock had a trading volume of 1,598,897 shares, compared to its average volume of 1,078,571. The firm has a 50 day moving average of $88.22 and a two-hundred day moving average of $70.57. Oruka Therapeutics has a 1 year low of $25.23 and a 1 year high of $115.51. The stock has a market cap of $6.92 billion, a price-to-earnings ratio of -51.51 and a beta of -0.34.

Insiders Place Their Bets

In other news, SVP Arjun Agarwal sold 10,000 shares of the company’s stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $106.66, for a total value of $1,066,600.00. Following the completion of the sale, the senior vice president directly owned 15,312 shares of the company’s stock, valued at approximately $1,633,177.92. This represents a 39.51% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Lawrence Klein sold 75,000 shares of the stock in a transaction dated Tuesday, September 1st. The stock was sold at an average price of $91.83, for a total transaction of $6,887,250.00. Following the sale, the chief executive officer owned 925,580 shares of the company’s stock, valued at $84,996,011.40. This trade represents a 7.50% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 179,950 shares of company stock valued at $16,492,680. Insiders own 23.49% of the company’s stock.

Analysts Set New Price Targets

ORKA has been the topic of a number of analyst reports. Piper Sandler restated an “overweight” rating on shares of Oruka Therapeutics in a report on Wednesday, October 7th. Wall Street Zen downgraded shares of Oruka Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, August 16th. BTIG Research reaffirmed a “buy” rating and set a $151.00 price objective on shares of Oruka Therapeutics in a report on Monday, October 19th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Oruka Therapeutics in a research report on Tuesday, October 13th. Finally, HC Wainwright reissued a “buy” rating on shares of Oruka Therapeutics in a report on Tuesday, October 27th. Ten analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $133.00.

Oruka Therapeutics Company Profile

Oruka Therapeutics is a clinical-stage biotechnology company developing long-acting antibody medicines for chronic inflammatory skin diseases. Its research focuses on pathways involved in conditions such as plaque psoriasis, with the goal of extending the time between treatments.

The company’s pipeline includes ORKA-001, an antibody targeting interleukin-23 (IL-23), and ORKA-002, which targets interleukin-17A and interleukin-17F (IL-17A/F). Both programs are being developed as potential treatments for inflammatory skin conditions.

Oruka was established around antibody programs developed by Paragon Therapeutics and became a publicly traded company in 2024 through a business combination with ARCA biopharma.